Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates

Total product revenue of $266.7 million for Full-Year 2023, representing 25% y-o-y growth; 31% y-o-y growth at constant exchange rate




VYVGART® was launched in September 2023 in China and we...

Related Keywords

Macau ,Hong Kong ,United States ,Taiwan ,China ,Efgartigimod Fcrn ,Josh Smiley ,Zai Lab ,National Medical Products Administration ,Clinical Development ,Zai Lab Forward ,Exchange Commission ,Drug Administration ,Zai Lab Limited ,Chief Executive Officer ,Chief Operating Officer ,American Deposit Share ,Treating Fields ,Greater China ,Premarket Approval ,Tumor Treating Fields ,Marketing Authorization Application ,Bristol Myers Squibb ,Prescription Drug User Fee Act ,New Drug Application ,Infectious Disease ,Biologics License Application ,Major Milestones ,Tumor Proportion Score ,Tissue Factor ,Autoimmune Disorders ,Infectious Diseases ,Private Securities Litigation Reform Act ,Ended December ,Share Subdivision ,Markets ,